Holen Sie sich die Stockscreener-App
0.9021
1.31%
-0.012
Handel nachbörslich:
.92
0.0179
+1.98%
Schlusskurs vom Vortag:
$0.9141
Offen:
$0.95
24-Stunden-Volumen:
175.88K
Relative Volume:
1.11
Marktkapitalisierung:
$18.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.53M
KGV:
-0.2465
EPS:
-3.66
Netto-Cashflow:
$-39.93M
1W Leistung:
-15.69%
1M Leistung:
-8.84%
6M Leistung:
-31.66%
1J Leistung:
-41.04%
1-Tages-Spanne:
$0.871
$0.95
1-Wochen-Bereich:
$0.86
$1.1001
52-Wochen-Spanne:
$0.8531
$3.10
Unity Biotechnology Inc Stock (UBX) Company Profile
Firmenname
Unity Biotechnology Inc
Sektor
Branche
Telefon
(650) 416-1192
Adresse
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie UBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
0.9021 | 18.42M | 0 | -52.53M | -39.93M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-16 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-01-04 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-11-10 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-06-28 | Hochstufung | Citigroup | Sell → Buy |
| 2021-06-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-16 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-08-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-08-17 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-03-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Eingeleitet | Mizuho | Buy |
| 2018-05-29 | Eingeleitet | Citigroup | Buy |
| 2018-05-29 | Eingeleitet | Goldman | Neutral |
| 2018-05-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Unity Biotechnology Inc Aktie (UBX) Neueste Nachrichten
Unity Biotechnology (UBX) to Release Earnings on Tuesday - Defense World
'It's a mess out there': More biotech layoffs mean stiff competition for jobs at emerging companies - The Business Journals
Renaissance Technologies LLC Sells 16,759 Shares of Unity Biotechnology, Inc. (NASDAQ:UBX) - Defense World
Bluebird pleads for deal support; Unity, Mersana lay off staff - BioPharma Dive
Biotech company once valued at $700 million slashes entire workforce - MSN
Bay Area biotech company lays off every single worker, including CEO - SFGATE
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
UNITY Biotechnology (UBX) Reports Promising 36-Week Results from ASPIRE Trial | UBX Stock News - GuruFocus
Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study - TipRanks
UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force - marketscreener.com
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates - The Manila Times
UNITY Biotechnology Announces Complete 36-Week Results from - GlobeNewswire
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of ... - Bluefield Daily Telegraph
UNITY's New DME Treatment Rivals Aflibercept in Phase 2b Trial, Company Explores Strategic Options - Stock Titan
UNITY Biotechnology to Present 36-Week Data from ASPIRE Phase 2B Study at ARVO 2025 Annual Meeting - Nasdaq
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting - The Manila Times
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
Chardan Capital Brokers Decrease Earnings Estimates for UBX - Defense World
Form 8-KCurrent report - ADVFN
HC Wainwright Issues Positive Outlook for UBX Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Chardan Capital Reaffirms “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Unity Biotechnology Reports Q1 2025 Financials and Study Updates - TipRanks
H.C. Wainwright maintains $4 target on Unity Biotech stock - Investing.com Australia
Unity Biotechnology (UBX) Reports $16.9M in Cash, Prepares for F - GuruFocus
H.C. Wainwright maintains $4 target on Unity Biotech stock By Investing.com - Investing.com Nigeria
UNITY Biotechnology (UBX) Shows Promise with Senolytic UBX1325 i - GuruFocus
UNITY Biotechnology Announces Publication in NEJM Evidence - GlobeNewswire
Revolutionary DME Drug Maintains Vision Improvement for 12 Months After Just One Dose, NEJM Study Shows - Stock Titan
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial R - GuruFocus
UNITY Biotechnology Reports Q1 2025 Financial Results and ASPIRE Study Data on UBX1325 for Diabetic Macular Edema - Nasdaq
Unity Biotechnology, Inc. SEC 10-Q Report - TradingView
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
UNITY's Eye Disease Drug Matches Standard Treatment at 36 Weeks: Key Trial Results Revealed - Stock Titan
Unity Biotechnology stock hits 52-week low at $0.94 By Investing.com - Investing.com Canada
Unity Biotechnology stock hits 52-week low at $0.94 - Investing.com
Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock By Investing.com - Investing.com Australia
Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock - Investing.com
Unity Biotechnology Executives Sell Shares for Tax Obligations - TradingView
HC Wainwright Has Pessimistic Outlook of UBX FY2026 Earnings - The AM Reporter
What is HC Wainwright’s Estimate for UBX FY2026 Earnings? - Defense World
Unity Biotechnology (NASDAQ:UBX) Price Target Lowered to $4.00 at Chardan Capital - Defense World
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating - Investing.com Australia
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study - MSN
Unity Biotechnology price target lowered to $4 from $6 at Chardan - TipRanks
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating By Investing.com - Investing.com South Africa
UNITY Biotechnology tanks on mixed results for eye disease drug - The Pharma Letter
Mizuho maintains Unity Biotechnology Outperform rating By Investing.com - Investing.com South Africa
Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating - Marketscreener.com
Finanzdaten der Unity Biotechnology Inc-Aktie (UBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):